Identification of Novel Targetable Kinases in SR-a GvHD

In this study, the investigators aim to identify novel targetable kinases in SR-a GvHD patient samples and investigate their role in different immune cell subtypes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Graft Versus Host Disease Graft vs Host Disease Immune System Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Corticosteroids are the first-line treatment of a GvHD, however many patients do not respond to corticosteroids. Patients with steroid-refractory a GvHD (SR-a GVHD) have a low 1-year survival rate. In this study, the investigators aim to identify and validate novel targetable kinases in SR-a GvHD patient peripheral blood mononuclear cells (PBMCs) by using a kinase-specific proteomic approach, and thereafter to investigate the role of the identified kinases in different immune cell subtypes by analyzing biopsies taken from SR- a GvHD patients.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

allo-transplanted
confirmed diagnosis of a GvHD
age ≥ 18 years
peripheral blood samples and biopsies available
written informed consent
ability to understand the nature of the study and the study-related procedures and to comply with them

Exclusion criteria

age < 18 years
lack of informed consent
patients that cannot be classified in one of the 2 groups (steroid-refractory, steroid-responsive)

Treatment and study plan

Primary outcomes

Identification of differentially regulated kinases

Time frame: 3 years

Bead-based Kinase Assay enrichment (Knet beads) of PBMC lysates

Secondary outcomes

Analysis of protein expression

Time frame: 3 years

Analysis of PBMC lysates by western blot
Analysis of immune cell subtype

Time frame: 3 years

Immunohistochemistry of intestinal biopsies

Sponsors and collaborators

Lead sponsor

University of Freiburg

Other

Registry information

Official study title

Investigation of Novel Targetable Kinases in Steroid-refractory Acute Graft-versus-host Disease

Important dates

Study start: 2017
Primary completion: 2019
Study completion: 2019
First posted: Apr 13, 2020
Registry last updated: Apr 13, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed